Provided by Tiger Trade Technology Pte. Ltd.

Verastem

5.70
-0.2300-3.88%
Post-market: 5.840.1393+2.44%18:50 EST
Volume:1.01M
Turnover:5.80M
Market Cap:429.32M
PE:-1.43
High:6.01
Open:5.90
Low:5.65
Close:5.93
52wk High:11.25
52wk Low:4.01
Shares:75.32M
Float Shares:57.38M
Volume Ratio:0.52
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9773
EPS(LYR):-3.6580
ROE:-2888.71%
ROA:-66.06%
PB:-27.65
PE(LYR):-1.56

Loading ...

Verastem updates oncology strategy in new corporate presentation

TIPRANKS
·
Jan 09

RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 08

Verastem Ends Lung Cancer Trial, Reallocates Resources

Benzinga_recent_news
·
Jan 03

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday

Benzinga_recent_news
·
Dec 30, 2025

BRIEF-Verastem Oncology Provides Update On Ramp 203 Phase 1/2 Clinical Trial

Reuters
·
Dec 30, 2025

Verastem Oncology to End RAMP 203 Trial of Lung Cancer Treatment

Dow Jones
·
Dec 30, 2025

Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC

Reuters
·
Dec 30, 2025

Verastem Oncology Provides Update on Ramp 203 Phase 1/2 Clinical Trial for Advanced Kras G12c Mutant Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Dec 30, 2025

Verastem Inc - Discontinues Ramp 203 Trial for Kras G12c-Mutated Nsclc

THOMSON REUTERS
·
Dec 30, 2025

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Simply Wall St.
·
Dec 26, 2025

Verastem Names John Johnson Chairman and Michael Kauffman President of Development

Reuters
·
Dec 20, 2025

BRIEF-Verastem Oncology Announces Transition Plan To Accelerate Next Phase Of Growth

Reuters
·
Dec 16, 2025

Verastem Names Michael Kauffman President of Development and John Johnson Chairman

Reuters
·
Dec 16, 2025

Verastem Inc: Ramp 301 Phase 3 Confirmatory Trial Topline Data Anticipated in Mid-2027

THOMSON REUTERS
·
Dec 16, 2025

Verastem Inc - John Johnson Appointed as Chairman of the Board

THOMSON REUTERS
·
Dec 16, 2025

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

THOMSON REUTERS
·
Dec 16, 2025

Verastem CEO Dan Paterson Reports Sale of Common Shares

Reuters
·
Dec 13, 2025

Verastem CEO Dan Paterson Reports Sale of Common Shares

Reuters
·
Dec 10, 2025

Verastem Inc. President and CEO Dan Paterson Reports Sale of Common Shares

Reuters
·
Dec 05, 2025

Verastem CEO Dan Paterson Reports Sale of Common Shares

Reuters
·
Dec 02, 2025